ConductScience.org, home

Paper36936142

Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.

Zhou P and 5 others. Front Endocrinol (Lausanne), 2023. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis. Papers, record 36936142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36936142

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.
PubMed
Journal
Front Endocrinol (Lausanne)
PubMed
Year
2023
PubMed
Publication types
Meta-Analysis, Systematic Review, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
2.77
iCite
Revised in PubMed
2025-06-26
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhou PPeipei
2Tan YYing
3Hao ZZhenning
4Xu WWeilong
5Zhou XXiqiao
6Yu JJiangyi

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Sodium-Glucose Transporter 2 InhibitorsMajor topic
Fatty LiverMajor topic
Elasticity Imaging TechniquesMajor topic
Humans
Liver Cirrhosis

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133782057The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.BMJ2021https://conductscience.org/library/papers/33782057PubMed
227462372Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.Diabetol Metab Syndr2016https://conductscience.org/library/papers/27462372PubMed
325524443Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.BMC Med Res Methodol2014https://conductscience.org/library/papers/25524443PubMed
434602251Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology2021https://conductscience.org/library/papers/34602251PubMed
534507895The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis.Dig Liver Dis2022https://conductscience.org/library/papers/34507895PubMed
630178600
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Diabetes Obes Metab2019https://conductscience.org/library/papers/30178600PubMed
714698338Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.Ultrasound Med Biol2003https://conductscience.org/library/papers/14698338PubMed
831963648Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial.J Clin Med2020https://conductscience.org/library/papers/31963648PubMed
920870345
Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes.
Ultrasound Med Biol2010https://conductscience.org/library/papers/20870345PubMed
1036910362Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.Afr Health Sci2022https://conductscience.org/library/papers/36910362PubMed
1129286050Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.Nat Rev Endocrinol2018https://conductscience.org/library/papers/29286050PubMed
1211003611Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.Hepatology2000https://conductscience.org/library/papers/11003611PubMed
1330780126Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease.Pharmacol Rep2019https://conductscience.org/library/papers/30780126PubMed
1434858740Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes.Cureus2021https://conductscience.org/library/papers/34858740PubMed
1535980569Ultrasound and FibroScan® Controlled Attenuation Parameter in patients with MAFLD: head to head comparison in assessing liver steatosis.Endocrine2022https://conductscience.org/library/papers/35980569PubMed
1635483674Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus.Diabetes Metab J2022https://conductscience.org/library/papers/35483674PubMed
1735089884Non-invasive tests of non-alcoholic fatty liver disease.Chin Med J (Engl)2022https://conductscience.org/library/papers/35089884PubMed
1827683581Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range.Stat Methods Med Res2018https://conductscience.org/library/papers/27683581PubMed
1926707365Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016https://conductscience.org/library/papers/26707365PubMed
2027183219Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis.Hepatol Res2016https://conductscience.org/library/papers/27183219PubMed

See all 47 referencesDownload CSV of references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
42967591
Comparative Efficacy and Safety of Saroglitazar and Dapagliflozin on Hepatic Steatosis and Glycemic Control in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A 25-Week Prospective Multicenter Comparative Cohort Study.
Endocrinol Diabetes Metab2026https://conductscience.org/library/papers/42967591PubMed
42517896Selective SGLT2 inhibitors in MASLD/MASH: an outcome-specific systematic review and meta-analysis of hepatic and cardiometabolic outcomes.Acta Diabetol2026https://conductscience.org/library/papers/42517896PubMed
42345092SGLT2 Inhibitors Promote Diabetic Wound Healing Via AMPK/AKT/mTORC1-Regulated Endothelial Angiogenesis.Arterioscler Thromb Vasc Biol2026https://conductscience.org/library/papers/42345092PubMed
41958639Natriuretic Effect of Dapagliflozin in Cirrhosis With Ascites: A Randomized, Placebo-Controlled Crossover Trial.Int J Hepatol2026https://conductscience.org/library/papers/41958639PubMed
41615833Effects of short-term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP-ELM study.J Diabetes Investig2026https://conductscience.org/library/papers/41615833PubMed
41535629Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study.Hepatol Int2026https://conductscience.org/library/papers/41535629PubMed
41497678Role of sodium-glucose cotransporter 2 inhibitors in liver diseases.World J Exp Med2025https://conductscience.org/library/papers/41497678PubMed
41157142Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes and Beyond: Mechanisms, Pleiotropic Benefits, and Clinical Use-Reviewing Protective Effects Exceeding Glycemic Control.Molecules2025https://conductscience.org/library/papers/41157142PubMed
40872510SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40872510PubMed
40630104SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes.Front Endocrinol (Lausanne)2025https://conductscience.org/library/papers/40630104PubMed
40289065Adverse Liver and Renal Outcomes After Initiating SGLT-2i and GLP-1RA Therapy Among Patients With Diabetes and MASLD.J Diabetes2025https://conductscience.org/library/papers/40289065PubMed
40075451Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis.BMC Pharmacol Toxicol2025https://conductscience.org/library/papers/40075451PubMed
40004772SGLT2 Inhibitors: The First Endothelial-Protector for Diabetic Nephropathy.J Clin Med2025https://conductscience.org/library/papers/40004772PubMed
39812053Use of SGLT2 Inhibitors in Frail Older Adults is Associated with Increased Survival: A Retrospective Study.Curr Pharm Des2025https://conductscience.org/library/papers/39812053PubMed
39699846Limited preventive effects of empagliflozin against metabolic dysfunction-associated steatotic liver disease in a mouse model of fast food diet.Hormones (Athens)2025https://conductscience.org/library/papers/39699846PubMed
39625600Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial.Hepatol Int2025https://conductscience.org/library/papers/39625600PubMed
39599627Sodium-Glucose Cotransporter 2 Inhibitors Improve Body Composition by Increasing the Skeletal Muscle Mass/Fat Mass Ratio in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.Nutrients2024https://conductscience.org/library/papers/39599627PubMed
39270669Tree-based scan statistics to generate drug repurposing hypotheses: a test case using sodium-glucose cotransporter-2 inhibitors.Am J Epidemiol2024https://conductscience.org/library/papers/39270669PubMed
37634892Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.Clin Mol Hepatol2023https://conductscience.org/library/papers/37634892PubMed
37109700Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?Medicina (Kaunas)2023https://conductscience.org/library/papers/37109700PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36936142

GET https://conductscience.org/api/papers/v1/36936142/references?page=2